

Clinical Policy: Naloxegol (Movantik)

Reference Number: AZ.CP.PMN.171

Effective Date: 09.19.19

Last Review Date: 10.20

Line of Business: Arizona Medicaid (AzCH-CCP and Care1st)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Naloxegol (Movantik[®]) is an opioid antagonist.

FDA Approved Indication(s)

Movantik is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Arizona Complete Health-Complete Care Plan and Care1st that Movantik is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Opioid-Induced Constipation (must meet all):

1. Diagnosis of OIC;
2. Age \geq 18 years;
3. Member has been taking opioid(s) for \geq 4 weeks due to chronic pain not caused by active cancer;
4. Failure of 1 agent from each of the following classes while on opioid therapy, unless all are contraindicated or clinically significant adverse effects are experienced:
 - a. Stimulant laxative (e.g., bisacodyl, senna);
 - b. Osmotic laxative (e.g., lactulose, polyethylene glycol);
 - c. Stool softener (e.g., docusate);
5. Member has used one of the aforementioned agents in the past 30 days, unless contraindicated;
6. Failure of Amitiza[®], unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Amitiza.*
7. Dose does not exceed 25 mg per day (1 tablet per day).

Approval duration: 6 months

B. Other diagnoses/indications

CLINICAL POLICY

Naloxegol (Movantik)

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): AZ.CP.PMN.53 for Arizona Medicaid.

II. Continued Therapy

A. Opioid-Induced Constipation (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member continues to receive opioid therapy;
3. Member is responding positively to therapy;
4. If request is for a dose increase, new dose does not exceed 25 mg per day (1 tablet per day).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): AZ.CP.PMN.53 for Arizona Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – AZ.CP.PMN.53 for Arizona Medicaid.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

OIC: opioid-induced constipation

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|--------------------------|--|-------------------------------------|
| bisacodyl (Dulcolax®) | Oral: 5 to 15 mg QD Rectal: Enema, suppository: 10 mg (1 enema or suppository) QD | 15 mg/day PO; 10 mg/day rectally |

CLINICAL POLICY

Naloxegol (Movantik)

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|--|---|------------------------------------|
| senna (Senokot [®]) | 1 to 2 tablets (8.6 to 17.2 mg sennosides) PO BID | 8 tablets (68.8 mg sennosides)/day |
| lactulose | 10 to 20 g (15 to 30 mL or 1 to 2 packets) daily; may increase to 40 g (60 mL or 2 to 4 packets) daily if necessary | 60 mL or 2 to 4 packets/day |
| polyethylene glycol 3350 (MiraLax [®]) | 17 g (approximately 1 heaping tablespoon) of powder in 120 to 240 mL of fluid given PO QD | 34 g/day |
| docusate sodium (Colace [®]) | 50-300 mg/day PO given in single or divided doses | 360 mg/day |
| Amitiza [®] (lubiprostone) | OIC: 24 mcg PO BID | OIC: 48 mcg/day |

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction
 - Concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole)
 - Known serious or severe hypersensitivity reaction to Movantik or any of its excipients
- Boxed warning(s): none reported

V. Dosage and Administration

| Indication | Dosing Regimen | Maximum Dose |
|------------|---|--------------|
| OIC | 25 mg PO QD; if not tolerated, reduce to 12.5 mg QD | 25 mg daily |

VI. Product Availability

Tablets: 12.5 mg and 25 mg

VII. References

1. Movantik Prescribing Information. Wilmington, DE; AstraZeneca Pharmaceuticals LP; February 2018. Available at: <https://www.movantik.com/>. Accessed: Accessed June 30, 2020.
2. Kumar L, Barker C, Emmanuel A. Opioid-Induced Constipation: Pathophysiology, Clinical Consequences, and Management. *Gastroenterology Research and Practice*. 2014;2014:141737. doi:10.1155/2014/141737.

CLINICAL POLICY

Naloxegol (Movantik)

3. Argoff CE, Brennan MJ, Camilleri M, et al. Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. *Pain Med.* 2015 Dec;16(12):2324-37.
4. Pergolizzi JV, Raffa RB, Pappagallo M, et al. Peripherally acting μ -opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient preference and adherence. 2017;11:107-119. doi:10.2147/PPA.S78042.
5. Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. *Therap Adv Gastroenterol.* 2015 Jul;8(4):206-20.
6. Nelson AD, Camilleri M. Opioid-induced constipation: advances and clinical guidance. *Ther Adv Chronic Dis.* 2016 Mar; 7(2): 121–134.
7. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2018. Available at: <http://www.clinicalpharmacology-ip.com/>.
8. Camilleri M, Lembo A, Katzka DA. Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. *Clin Gastroenterol Hepatol.* 2017 Sep;15(9):1338-1349.
9. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guidelines on the Medical Management of Opioid-Induced Constipation. *Gastroenterol.* 2019;156:218-226.

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|--|----------|-------------------|
| Policy created. | 09.18.19 | 09.19 |
| 4Q 2020 annual review: no significant changes; references reviewed and updated. | 09.29.20 | 10.20 |
| Added Care1st logo. Added verbiage to specify that criteria also applies to Care1st. | 5.10.21 | 04.21 |

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage

CLINICAL POLICY

Naloxegol (Movantik)

decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.